Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03801356 · ClinicalTrials.gov registry record · Phase 4

Threshold Response of Lumbar Selective Nerve Root Block in Predicting Good Outcome Following Lumbar Foraminotomy

A Phase 4 study, sponsored by The Cleveland Clinic.

Terminated
Registry status
Phase 4
Development phase
11
Enrollment target

NCT03801356 is a Phase 4 study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 11 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03801356, a Phase 4 study, was terminated before completion, sponsored by The Cleveland Clinic.

TERMINATED
Registry status
Phase 4
Development phase
11 participants
Enrollment target

Study Summary

SNRB, as measured by the change in pain and objective functional ability, can solicit crucial information regarding a patient's clinical picture and can predict a patient's outcome post-surgery. By using the walk test as an objective functional assessment, the aim is to better standardize the threshold for a positive response to SNRB. In summary, SNRB, despite utilized frequently in the diagnostic work-up with patients with lumbar radiculopathy, vary widely in their sensitivity and specificity. The reasons, as outlined above, are multifactorial. The proposed study aims to minimize the known limitations of these injections and prospectively define their positive and negative predictive value in a homogenous group of patients undergoing surgery for lumbar foraminal stenosis and radiculopathy. The design will define a threshold of response utilizing both subjective and objective measures and more accurately predict excellent results following surgery.

Interventions

  • DRUG Selective Nerve Root Block

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2018-08-23
Est. Completion 2020-12-15
Phase Phase 4

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT03801356

The ClinicalTrials.gov registry entry for NCT03801356 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Selective Nerve Root Block is the first listed.

NCT03801356 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03801356 about?

NCT03801356 is a clinical study titled "Threshold Response of Lumbar Selective Nerve Root Block in Predicting Good Outcome Following Lumbar Foraminotomy". SNRB, as measured by the change in pain and objective functional ability, can solicit crucial information regarding a patient's clinical picture and can predict a patient's outcome post-surgery. By using the walk test as an objective functional assessment, the aim is to better standardize the thresh...

What is the current status of trial NCT03801356?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2018-08-23. Estimated completion is 2020-12-15.

What interventions are being tested in trial NCT03801356?

The interventions under investigation include: Selective Nerve Root Block (DRUG).

Who is sponsoring clinical trial NCT03801356?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.